Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature.

MLA

Caddeo, Giulia, et al. “Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-Dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature.” Clinical Hematology International, vol. 5, no. 2–3, June 2023, pp. 130–38. EBSCOhost, https://doi.org/10.1007/s44228-023-00038-6.

APA

Caddeo, G., Tecchio, C., Chinello, M., Balter, R., Zaccaron, A., Vitale, V., Pezzella, V., Bonetti, E., Pillon, M., Carraro, E., Mussolin, L., & Cesaro, S. (2023). Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature. Clinical Hematology International, 5(2–3), 130–138. https://doi.org/10.1007/s44228-023-00038-6

Chicago

Caddeo, Giulia, Cristina Tecchio, Matteo Chinello, Rita Balter, Ada Zaccaron, Virginia Vitale, Vincenza Pezzella, et al. 2023. “Refractory Anaplastic Large Cell Lymphoma Rescued by the Combination of the Second-Generation ALK Inhibitor Brigatinib, High-Dose Chemotherapy and Allogeneic Stem Cell Transplantation: A Case Report and Review of the Literature.” Clinical Hematology International 5 (2–3): 130–38. doi:10.1007/s44228-023-00038-6.